GlassScriptPhysician profile
John R Meek
NPI 1891796298
$12,330.62
in general payments reported to CMS, 2019-2025
31 companies · $2,791 in 2025
The $2,791 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $567 · 2021: $751 · 2022: $1,686 · 2023: $2,107 · 2024: $2,591 · 2025: $2,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,467 · Education: $22.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,467.10 |
| Education | $22.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,820.77 | 2019-2025 | Biktarvy, Veklury, Descovy |
| Shionogi INC | $1,472.88 | 2021-2025 | Fetroja |
| Viiv Healthcare Company | $1,179.00 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $1,132.87 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Insmed, INC. | $1,017.39 | 2019-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $862.64 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $608.78 | 2019-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $562.61 | 2019-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $549.30 | 2022-2025 | Xerava, Zevtera, Xacduro |
| Abbvie INC. | $403.85 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $262.62 | 2023-2025 | Vowst |
| Tetraphase Pharmaceuticals, INC. | $221.73 | 2019-2025 | |
| Allergan, INC. | $195.91 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $147.12 | 2019-2022 | |
| Janssen Biotech, INC. | $124.46 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.27 | 2024 | Xifaxan |
| Theratechnologies INC. | $99.38 | 2019-2025 | Trogarzo, Egrifta |
| Ferring Pharmaceuticals INC. | $95.04 | 2024-2025 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $85.35 | 2024-2025 | Vibativ |
| Pfizer INC. | $83.45 | 2022-2025 | |
| Csl Behring | $79.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Urgo Medical North America, LLC | $27.01 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Invivyd INC | $26.63 | 2024 | Pemgarda |
| Organogenesis INC. | $24.38 | 2024 | |
| Pharming Healthcare, INC. | $21.45 | 2024 | Ruconest |
| Vyera Pharmaceuticals, LLC | $17.48 | 2022 | |
| Shire North American Group INC | $17.25 | 2019 | |
| Biomerieux INC | $16.44 | 2025 | Filmarray Torch Module |
| Romark Laboratories, Lc | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.